The invention relates to analysis of the MSI (microsatellite instability) state which can serve as an auxiliary diagnosis marker for tumor immunotherapy (PD-1/PD-L1). The MSI of tumor cells of human beings is detected on the basis of a fluorescent PCR platform, and five of more mononucleotide repeat loci (NR-21, NR-24, BAT-25, BAT-26 and MONO27) reported in documents and internationally are selected for analysis of the MSI state. Besides, two pentanucleotide repeat loci (Penta C and Penta D) are selected for quality control of samples and are mainly used for detecting mixing and pollution of the samples. A fluorescently labeled primer is adopted, and besides, 7 loci are amplified; by comparison with other products, the amplification conditions are simplified, amplification can be performed on common PCR equipment, signals are stronger in combination with capillary electrophoresis analysis, the operation is simple, economical and practical properties are realized, the MSI state of a patient who receives or is going to receive tumor immunotherapy (PD-1/PD-L1) can be detected within short time, and guiding significance is given as soon as possible for clinical treatment.